196 related articles for article (PubMed ID: 29093741)
1. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.
Levada OA; Troyan AS
Ann Gen Psychiatry; 2017; 16():38. PubMed ID: 29093741
[TBL] [Abstract][Full Text] [Related]
2. Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA.
Tu KY; Wu MK; Chen YW; Lin PY; Wang HY; Wu CK; Tseng PT
Medicine (Baltimore); 2016 Jan; 95(4):e2411. PubMed ID: 26825882
[TBL] [Abstract][Full Text] [Related]
3. Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD).
Mosiołek A; Mosiołek J; Jakima S; Pięta A; Szulc A
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362162
[TBL] [Abstract][Full Text] [Related]
4. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.
Sharma AN; da Costa e Silva BF; Soares JC; Carvalho AF; Quevedo J
J Affect Disord; 2016 Jun; 197():9-20. PubMed ID: 26956384
[TBL] [Abstract][Full Text] [Related]
5. Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction.
Liu CS; Carvalho AF; McIntyre RS
CNS Neurol Disord Drug Targets; 2014; 13(10):1693-707. PubMed ID: 25470395
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin-like growth factor 1 and late-life depression: a population-based study.
van Varsseveld NC; van Bunderen CC; Sohl E; Comijs HC; Penninx BW; Lips P; Drent ML
Psychoneuroendocrinology; 2015 Apr; 54():31-40. PubMed ID: 25678185
[TBL] [Abstract][Full Text] [Related]
7. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users.
Bot M; Milaneschi Y; Penninx BW; Drent ML
Psychoneuroendocrinology; 2016 Jun; 68():148-55. PubMed ID: 26974499
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder.
Pan Z; Grovu RC; Cha DS; Carmona NE; Subramaniapillai M; Shekotikhina M; Rong C; Lee Y; McIntyre RS
CNS Neurol Disord Drug Targets; 2017; 16(8):891-899. PubMed ID: 28933261
[TBL] [Abstract][Full Text] [Related]
9. Association between IGF-1 levels and MDD: a case-control and meta-analysis.
Qiao X; Yan J; Zang Z; Xi L; Zhu W; Zhang E; Wu L
Front Psychiatry; 2024; 15():1396938. PubMed ID: 38919642
[TBL] [Abstract][Full Text] [Related]
10. Possible contribution of IGF-1 to depressive disorder.
Szczęsny E; Slusarczyk J; Głombik K; Budziszewska B; Kubera M; Lasoń W; Basta-Kaim A
Pharmacol Rep; 2013; 65(6):1622-31. PubMed ID: 24553010
[TBL] [Abstract][Full Text] [Related]
11. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.
McIntyre RS; Xiao HX; Syeda K; Vinberg M; Carvalho AF; Mansur RB; Maruschak N; Cha DS
CNS Drugs; 2015 Jul; 29(7):577-89. PubMed ID: 26290264
[TBL] [Abstract][Full Text] [Related]
12. Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective.
Levada OA; Troyan AS
Med Hypotheses; 2020 May; 138():109610. PubMed ID: 32044543
[TBL] [Abstract][Full Text] [Related]
13. Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression.
Paslakis G; Blum WF; Deuschle M
Med Hypotheses; 2012 Aug; 79(2):222-5. PubMed ID: 22626951
[TBL] [Abstract][Full Text] [Related]
14. Towards a multi protein and mRNA expression of biological predictive and distinguish model for post stroke depression.
Yue Y; Jiang H; Liu R; Yin Y; Zhang Y; Liang J; Li S; Wang J; Lu J; Geng D; Wu A; Yuan Y
Oncotarget; 2016 Aug; 7(34):54329-54338. PubMed ID: 27527872
[TBL] [Abstract][Full Text] [Related]
15. Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review.
Chen YW; Lin PY; Tu KY; Cheng YS; Wu CK; Tseng PT
Neuropsychiatr Dis Treat; 2015; 11():925-33. PubMed ID: 25897228
[TBL] [Abstract][Full Text] [Related]
16. Aberrant interhemispheric functional connectivity in first-episode, drug-naïve major depressive disorder.
Yang H; Wang C; Ji G; Feng Z; Duan J; Chen F; Zhou XJ; Shi Y; Xie H
Brain Imaging Behav; 2019 Oct; 13(5):1302-1310. PubMed ID: 30145713
[TBL] [Abstract][Full Text] [Related]
17. The neural systems of emotion regulation and abnormalities in major depressive disorder.
Park C; Rosenblat JD; Lee Y; Pan Z; Cao B; Iacobucci M; McIntyre RS
Behav Brain Res; 2019 Jul; 367():181-188. PubMed ID: 30951753
[TBL] [Abstract][Full Text] [Related]
18. Disrupted reward circuits is associated with cognitive deficits and depression severity in major depressive disorder.
Gong L; Yin Y; He C; Ye Q; Bai F; Yuan Y; Zhang H; Lv L; Zhang H; Xie C; Zhang Z
J Psychiatr Res; 2017 Jan; 84():9-17. PubMed ID: 27673704
[TBL] [Abstract][Full Text] [Related]
19. Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease.
Darcet F; Gardier AM; Gaillard R; David DJ; Guilloux JP
Pharmaceuticals (Basel); 2016 Feb; 9(1):. PubMed ID: 26901205
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
